Core Viewpoint - The recent inclusion of multiple Hong Kong stocks into the Stock Connect program has led to significant price volatility and increased trading activity, driven by various factors including index adjustments, new capital inflows, speculative trading, and limited share availability [1][2][4]. Group 1: Stock Performance - Several stocks, such as药捷安康-B and佰泽医疗, experienced dramatic price movements after being included in the Stock Connect, with药捷安康-B seeing a peak increase of over 1000% shortly after inclusion, followed by a sharp decline of 53.73% [2][4]. - The average trading volume for these stocks surged significantly post-inclusion, with some stocks experiencing increases in daily trading volume by several times to dozens of times compared to before [3][4]. Group 2: Reasons for Volatility - The adjustment of index constituents has led to passive buying from ETFs tracking these indices, contributing to the volatility of newly included stocks [4][5]. - The inclusion of these stocks has opened up opportunities for mainland investors, resulting in a notable influx of capital into these stocks [5][6]. - Speculative trading has also played a role, particularly in the healthcare sector, where stocks with innovative drug concepts have attracted attention [6][7]. - Many of the stocks included are relatively new to the market, with limited free-floating shares, making them more susceptible to extreme price fluctuations when capital flows in [6][7].

Group 1 - The company's revenue increased from RMB 51.89 million to RMB 100.05 million for the six months ending June 30, 2025, representing a year-on-year growth of 92.81% [1] - Gross profit rose to RMB 40.85 million, a year-on-year increase of 66.60%, primarily due to a significant increase in system sales and the number of hospitals and patients using the systems [1] - Research and development expenses increased from RMB 64.23 million to RMB 68.15 million, reflecting a year-on-year growth of 6.10% [1] Group 2 - The company has established a broad pipeline of digital therapy products, with core products commercialized for eight indications across four major types of cognitive disorders [2] - The company plans to implement strategies to drive future growth, including expanding system indications, accelerating commercialization, enhancing R&D capabilities, exploring international markets, and seeking strategic acquisition opportunities [2] - The company has helped over 200 hospitals in China establish cognitive centers, including leading hospitals certified as "National Medical Centers" by the National Health Commission [1][2]